The National Comprehensive Cancer Network Policy Summit emphasized the importance of integrating diversity, equity, and inclusion into the oncology workforce to improve cancer care outcomes and address disparities while navigating legal and societal challenges.
Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new safety profiles observed.
Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis.
Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.
The work might take long, but cancer advocate and survivor Matthew Zachary drove home the importance of advocacy to continue improving the lives of patients with cancer and provide them better options.
The potential value of these biomarkers may help differentiate acetylcholine receptor antibody seropositive (AChR+) myasthenia gravis (MG) from healthy patients.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Danish patients who were diagnosed with certain lymphomas and other B-cell malignancies demonstrated increased antimicrobial use for at least a decade before their diagnosis.
In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why stigma and shame continue to attach themselves to an HIV diagnosis and why policy efforts to overcome both must persist.
Here are 5 areas of specialty care that rural communities often lack, putting them at a distinct disadvantage for optimal short- and long-term health outcomes and highlighting inequitable access to care for those often living in economically disadvantaged areas.
During the first fireside chat at the Patient-Centered Oncology Care® meeting, Alyssa Schatz, MSW, of National Comprehensive Cancer Network, discussed work being done to improve care for patients with cancer.
The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.
The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.
New prevalence estimates of atrial fibrillation found that approximately 10.5 million US adults, or 5% of the population, have the condition.
The latest study findings suggest that acalabrutinib may be a safer option than ibrutinib for patients with chronic lymphocytic leukemia, offering a lower risk of serious cardiovascular and infection-related adverse events.
The rate of uninsurance in 2023 was 8.0%, a statistically insignificant change from the 7.9% uninsured rate in 2022.
Goals including addressing all of hunger and food insecurity, unmet needs for mental health services, and unstable housing or homelessness in people living with HIV are unlikely to meet their 2025 thresholds.
This interview accompanies the second podcast in our National Recovery Month series with Mandy Faubel, PhD, LCSW, UPMC Western Behavioral Health at Safe Harbor, and Rebekah Sedlock, DSW, LCSW, UPMC Insurance Services Division with Community Care.
An electronic version of the Symbol-Digit Modalities Test could enable people with multiple sclerosis (MS) to perform frequent remote cognitive assessments independently.
An update to the colonoscopy guidelines released by the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy could have implications on how colonoscopies are measured in the future.
New research reveals disparities in opioid prescribing by race among Medicare beneficiaries, sparking concerns about potential impacts on rehabilitation outcomes.
During the presidential debate, former President Donald Trump and Vice President Kamala Harris shared their differing visions for the future of the Affordable Care Act (ACA).
Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival (PFS) in patients with epithelial ovarian cancer (EOC) but not overall survival (OS).
During ESMO Congress 2024, sessions will focus on hot topics in therapeutic areas, such as antibody-drug conjugates; the latest trial data; health policy; and advances in technology.
A new proof-of-concept method reliably engineered a hotspot mutation of SF3B1, a gene-splicing gene, into diverse cancer cell lines, outperforming other contemporary editing approaches.
Social frailty in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) does not directly impact anxiety or depression but influences these conditions indirectly through social support.
The European approval comes months after the FDA’s approval of the first-of-its-kind treatment for pulmonary arterial hypertension (PAH).
An AI segmentation system was able to identify changes in retinal segmented features based on optical coherence tomography (OCT) images.
Policy changes, such as banning spread pricing and promoting transparency, are necessary to realign the pharmacy benefit manager (PBM) market and ensure that health care resources benefit patients and providers rather than being diverted by middlemen, according to panelists at the Community Oncology Alliance Payer Exchange Summit.
Matthew Smeltzer, PhD, University of Memphis, shares insights into his team's quality-of-care initiative to identify and combat gaps in care for patients with early-stage non–small cell lung cancer (NSCLC).
